BIOMAT Database Logo BIOMAT Database Logo

The PTPN22 R620W polymorphism in anti-neutrophil cytoplasmic antibody-associated vasculitis in Mexican Mestizos. 2016

Juan Carlos Zenteno, and Vicente Correa-Gómez, and Ericka N Pompa-Mera, and Guadalupe Lima, and Miguel Pedroza-Seres, and Luis Felipe Flores-Suárez
Department of Biochemistry, Faculty of Medicine, Universidad Nacional Autónoma de México felipe98@prodigy.net.mx.

UI MeSH Term Description Entries
D008800 Mexico A country in NORTH AMERICA, bordering the Caribbean Sea and the Gulf of Mexico, between BELIZE and the UNITED STATES, and bordering the North Pacific Ocean, between Guatemala and the UNITED STATES.
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012308 Risk Management The process of minimizing risk to an organization by developing systems to identify and analyze potential hazards to prevent accidents, injuries, and other adverse occurrences, and by attempting to handle events and incidents which do occur in such a manner that their effect and cost are minimized. Effective risk management has its greatest benefits in application to insurance in order to avert or minimize financial liability. (From Slee & Slee: Health care terms, 2d ed) Hospital Incident Reporting,Incident Reporting, Hospital,Hospital Incident Reportings,Incident Reporting,Incident Reportings, Hospital,Management, Risks,Reporting, Hospital Incident,Reportings, Hospital Risk,Voluntary Patient Safety Event Reporting,Hospital Risk Reporting,Hospital Risk Reportings,Incident Reportings,Management, Risk,Reporting, Hospital Risk,Reporting, Incident,Reportings, Hospital Incident,Reportings, Incident,Risk Reporting, Hospital,Risk Reportings, Hospital,Risks Management
D016133 Polymerase Chain Reaction In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. Anchored PCR,Inverse PCR,Nested PCR,PCR,Anchored Polymerase Chain Reaction,Inverse Polymerase Chain Reaction,Nested Polymerase Chain Reaction,PCR, Anchored,PCR, Inverse,PCR, Nested,Polymerase Chain Reactions,Reaction, Polymerase Chain,Reactions, Polymerase Chain
D054596 Protein Tyrosine Phosphatase, Non-Receptor Type 22 A subtype of non-receptor protein tyrosine phosphatases that is characterized by the presence of an N-terminal catalytic domain and a C-terminal PROLINE-rich domain. The phosphatase subtype is predominantly expressed in LYMPHOCYTES and plays a key role in the inhibition of downstream T-LYMPHOCYTE activation. Polymorphisms in the gene that encodes this phosphatase subtype are associated with a variety of AUTOIMMUNE DISEASES. Lymphoid Phosphatase,Lyp1 PTPase,Lyp2 PTPase,PTPN-22 Protein,PTPase Lyp,Protein-Tyrosine Phosphatase Lyp,Tyrosine Protein Phosphatase, Non-Receptor Type 22,PTPN 22 Protein,PTPase, Lyp1,PTPase, Lyp2,Protein Tyrosine Phosphatase Lyp,Protein Tyrosine Phosphatase, Non Receptor Type 22,Tyrosine Protein Phosphatase, Non Receptor Type 22
D056648 Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Group of systemic vasculitis with a strong association with ANCA. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls. ANCA-Associated Vasculitides,ANCA-Associated Vasculitis,Pauci-Immune Vasculitis,ANCA Associated Vasculitides,ANCA Associated Vasculitis,ANCA-Associated Vasculitide,Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis,Pauci Immune Vasculitis,Pauci-Immune Vasculitides,Vasculitide, ANCA-Associated,Vasculitides, ANCA-Associated,Vasculitides, Pauci-Immune,Vasculitis, ANCA-Associated,Vasculitis, Pauci-Immune
D020022 Genetic Predisposition to Disease A latent susceptibility to disease at the genetic level, which may be activated under certain conditions. Genetic Predisposition,Genetic Susceptibility,Predisposition, Genetic,Susceptibility, Genetic,Genetic Predispositions,Genetic Susceptibilities,Predispositions, Genetic,Susceptibilities, Genetic

Related Publications

Juan Carlos Zenteno, and Vicente Correa-Gómez, and Ericka N Pompa-Mera, and Guadalupe Lima, and Miguel Pedroza-Seres, and Luis Felipe Flores-Suárez
Anti-neutrophil cytoplasmic antibody-associated paraneoplastic vasculitis.
May 1994, Postgraduate medical journal,
Juan Carlos Zenteno, and Vicente Correa-Gómez, and Ericka N Pompa-Mera, and Guadalupe Lima, and Miguel Pedroza-Seres, and Luis Felipe Flores-Suárez
Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis.
January 2019, BMC rheumatology,
Juan Carlos Zenteno, and Vicente Correa-Gómez, and Ericka N Pompa-Mera, and Guadalupe Lima, and Miguel Pedroza-Seres, and Luis Felipe Flores-Suárez
Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis.
March 2023, Rheumatology and immunology research,
Juan Carlos Zenteno, and Vicente Correa-Gómez, and Ericka N Pompa-Mera, and Guadalupe Lima, and Miguel Pedroza-Seres, and Luis Felipe Flores-Suárez
Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis.
April 2006, Kidney international,
Juan Carlos Zenteno, and Vicente Correa-Gómez, and Ericka N Pompa-Mera, and Guadalupe Lima, and Miguel Pedroza-Seres, and Luis Felipe Flores-Suárez
Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis.
December 2019, Chinese medical journal,
Juan Carlos Zenteno, and Vicente Correa-Gómez, and Ericka N Pompa-Mera, and Guadalupe Lima, and Miguel Pedroza-Seres, and Luis Felipe Flores-Suárez
PTPN22 R620W polymorphism in the ANCA-associated vasculitides.
May 2012, Rheumatology (Oxford, England),
Juan Carlos Zenteno, and Vicente Correa-Gómez, and Ericka N Pompa-Mera, and Guadalupe Lima, and Miguel Pedroza-Seres, and Luis Felipe Flores-Suárez
Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis.
April 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Juan Carlos Zenteno, and Vicente Correa-Gómez, and Ericka N Pompa-Mera, and Guadalupe Lima, and Miguel Pedroza-Seres, and Luis Felipe Flores-Suárez
Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis.
January 2016, Indian journal of nephrology,
Juan Carlos Zenteno, and Vicente Correa-Gómez, and Ericka N Pompa-Mera, and Guadalupe Lima, and Miguel Pedroza-Seres, and Luis Felipe Flores-Suárez
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Kidney Transplantation.
December 2021, Medicina (Kaunas, Lithuania),
Juan Carlos Zenteno, and Vicente Correa-Gómez, and Ericka N Pompa-Mera, and Guadalupe Lima, and Miguel Pedroza-Seres, and Luis Felipe Flores-Suárez
Neutrophil FcgammaRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis.
March 2000, Clinical and experimental immunology,
Copied contents to your clipboard!